ANNALEE ALDAPE: Open Payments
NPI 1730945478 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,323 in 154 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $2,018 · 2025 $3,323
Food & beverage: $3,323
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 44 | $715 |
| Ipsen Biopharmaceuticals, Inc | 14 | $438 |
| Madrigal Pharmaceuticals | 12 | $426 |
| Janssen Biotech, Inc. | 10 | $375 |
| Phathom Pharmaceuticals, Inc. | 14 | $273 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $206 |
| Gilead Sciences, Inc. | 11 | $184 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $183 |
| Lilly USA, LLC | 10 | $161 |
| GENZYME CORPORATION | 5 | $145 |
Products named: REZDIFFRA, TREMFYA, IQIRVO, VOQUEZNA, LINZESS, XIFAXAN, RINVOQ, DUPIXENT.
Industry payments across TX — which companies pay providers there.
